ReviewFrontiers in neurology
PVN mechanisms in OSA comorbidities: from intermittent hypoxia-stress to therapy.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive Sleep Apnea (OSA) is a common sleep-disordered breathing condition characterized by recurrent upper airway collapse, chronic intermittent hypoxia (CIH), and sleep fragmentation. Beyond daytime dysfunction, OSA is strongly associated with cardiovascular and neuropsychiatric comorbidities, particularly hypertension and depression. The paraventricular nucleus of the hypothalamus (PVN), a central hub for autonomic regulation and stress integration, plays a pivotal role in mediating these outcomes. This review synthesizes recent evidence on the synergistic interplay between CIH and chronic stress within the PVN. We highlight three core mechanisms-neuronal plasticity, neuroinflammation and oxidative stress, and epigenetic reprogramming-that collectively drive sustained sympathetic overactivation and hypothalamic-pituitary-adrenal (HPA) axis dysregulation. These central alterations form the neurobiological basis of OSA-related hypertension and contribute to shared pathways with mood disorders, including oxidative stress and ferroptosis. Finally, we summarize emerging diagnostic and therapeutic advances, such as non-invasive biomarkers, phenotype-specific pharmacotherapies, and precision neuromodulation approaches. Future directions include the development of composite animal models, targeted epigenetic interventions, and circuit-specific modulation strategies. Together, these insights provide a framework for mechanism-based and stratified management of OSA and its comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.